Prosensa Holding B.V. (RNA) 18.65 $RNA
Prosensa Announces Voluntary Delisting and Advance Liquidation Distribution
GlobeNewswire - Tue Feb 10, 11:16AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"
, the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that, on February 11, 2015, it will file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act" (the "Form 25" , with the Securities Exchange Commission ("SEC" in order to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares" from the NASDAQ Global Select Market ("NASDAQ" , which will become effective 10 days after filing. NASDAQ has advised the Company that it will suspend trading of the Shares after the market closes on February 11, 2015. As such, shareholders of the Company will not be able to trade their shares on NASDAQ thereafter.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
3 Biotech Stocks to Buy in February
Motley Fool Staff - Motley Fool - Mon Feb 02, 9:01AM CST
When it comes to figuring out the best stocks to buy in any given month or year, crystal balls can be hazy, but our top Motley Fool contributors have scoured SEC filings, read industry trade journals, and crunched numbers to uncover three biotech...
FLML: 14.15 (+0.15), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), CELG: 115.88 (+0.16)
Prosensa Announces Intent to Voluntarily Delist From NASDAQ
GlobeNewswire - Fri Jan 30, 7:36AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company" , the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that it intends to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares" , from the NASDAQ Global Select Market ("NASDAQ" . Upon satisfaction of the applicable requirements for deregistration, Prosensa also intends to deregister the Shares under the Securities Exchange Act of 1934, as amended (the "Exchange Act" and to suspend its reporting obligations under the Exchange Act once it is eligible to do so.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
BioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period
GlobeNewswire - Fri Jan 30, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the final results of, and the completion of the subsequent offering period relating to, the previously announced tender offer by its subsidiaries, BioMarin Falcons B.V. and BioMarin Giants B.V. (together, "Purchaser" , to acquire all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA) at a purchase price of $17.75 per share, net to the seller in cash (the "Cash Consideration" , plus one non-transferrable contingent value right to receive cash payments of up to $4.14 per share in the aggregate upon the achievement of certain product approval milestones ("CVR" , in each case, without interest thereon and less any applicable withholding taxes.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 5:00PM CST
BioMarin (BMRN) will be raising approximately $792.6 million through the issuance of the shares in order to finance the Prosensa acquisition.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), ALXN: 182.29 (+6.02), AMGN: 153.48 (+0.30)
Marathon Pharma DMD drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:38PM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), PFE: 34.64 (-0.23), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
3 Warning Signs You've Invested in a Dangerous Biotech Stock
Motley Fool Staff - Motley Fool - Sat Jan 17, 10:59AM CST
Source: Flickr user epSos .de . There might not be a bell that will ring to alert investors when they have put their money in the wrong biotech stock, but there are warning signals that can help them avoid owning the most dangerous biotech...
INO: 6.80 (-0.15), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), GSK: 47.94 (+1.99)
BioMarin Announces Completion of Tender Offer for Prosensa's Shares and Commences Subsequent Offering Period
GlobeNewswire - Thu Jan 15, 7:59AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it completed the initial offering period for the previously announced tender offer for all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA). As a result, BioMarin will purchase approximately 93.4% of Prosensa's outstanding shares pursuant to the initial offering period for the tender offer. BioMarin also announced that it has commenced a subsequent offering period to provide Prosensa shareholders who have not yet tendered their shares the opportunity to do so. The subsequent offering period is scheduled to expire at 6:00 p.m., New York City time, on January 29, 2015.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
Update: BioMarin To Acquire Prosensa Holding N.V.
Maudes Capital - at Seeking Alpha - Thu Jan 15, 7:27AM CST
BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
BioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 4:10PM CST
BioMarin (BMRN) raised its 2014 guidance for Vimizim sales and presented encouraging interim data from an ongoing phase I/II pivotal study on Batten disease candidate, BMN 190.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23)
Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer
GlobeNewswire - Tue Jan 13, 7:56AM CST
Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that during an extraordinary general meeting of shareholders held today, Prosensa obtained shareholder approval for certain matters relating to the previously disclosed tender offer by BioMarin to purchase all of the outstanding shares of Prosensa.
RNA: 18.65 (unch)
Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year
at The Street - Mon Jan 12, 8:47AM CST
The company presents at the J.P. Morgan Healthcare Conference on Thursday.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), SRPT: 12.76 (+0.11)
Why Sarepta Therapeutics Inc. Stock Tumbled 15% in December
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 09, 6:04AM CST
SRPT data by YCharts What: Shares of Sarepta Therapeutics , a clinical-stage biotechnology company primarily focused on developing therapies to treat Duchenne muscular dystrophy, or DMD, tumbled 15% in December according to data from ...
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), SRPT: 12.76 (+0.11)
Cramer's Mad Money - Best Biotechs Of 2014 (1/6/15)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Jan 07, 4:38AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday January 6. Best Biotechs of 2014: Isis Pharmaceuticals (NASDAQ: ISIS ), BioMarin (NASDAQ: BMRN ), OvaScience (NASDAQ: OVAS ), Agios (NASDAQ: AGIO ),...
BLUE: 90.70 (+0.93), GE: 25.15 (+0.26), BMRN: 100.76 (+1.98), OVAS: 44.32 (+0.87), XOM: 93.37 (+1.00), TGTX: 13.13 (-0.19), WFC: 55.33 (+0.47), BA: 149.73 (+1.64), GLUU: 5.12 (+0.14), LUV: 43.30 (-0.20), T: 34.66 (+0.05), TTWO: 28.40 (+0.96), GT: 25.91 (-0.30), SAVE: 79.32 (-0.80), ISIS: 63.86 (-0.43), RNA: 18.65 (unch), IBM: 160.40 (+1.88), AAL: 48.39 (+0.51), MCD: 95.65 (+0.56), RCPT: 115.83 (-0.66), AGI: 5.78 (+0.03), TWTR: 48.50 (+0.55), CVX: 112.78 (+1.92), VZ: 49.31 (-0.21)
Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains
at The Street - Tue Jan 06, 7:25PM CST
The markets are presenting a buying opportunity at current levels, but only if you know which stocks to buy, Cramer says.
TSLA: 203.77 (+0.89), GE: 25.15 (+0.26), OVAS: 44.32 (+0.87), NMM: 12.37 (+0.24), XOM: 93.37 (+1.00), T: 34.66 (+0.05), ESPR: 67.13 (-0.33), IBM: 160.40 (+1.88), IRE: 14.54 (+0.81), DTV: 87.51 (-0.32), PTCT: 53.37 (-0.74), RCPT: 115.83 (-0.66), TEG: 75.56 (-1.61), PPG: 236.77 (+3.74), WAG: 76.05 (-0.49), BLUE: 90.70 (+0.93), TGTX: 13.13 (-0.19), WFC: 55.33 (+0.47), BA: 149.73 (+1.64), RAD: 8.34 (+0.25), ISIS: 63.86 (-0.43), RNA: 18.65 (unch), ACHN: 10.89 (-0.20), JCP: 8.05 (+0.14), CVS: 102.63 (-0.37), MCD: 95.65 (+0.56), AGIO: 118.55 (+0.11), CVX: 112.78 (+1.92), VZ: 49.31 (-0.21), FOLD: 8.36 (-0.11)
Merger Arbitrage Mondays - January 5, 2015
Asif Suria - at Seeking Alpha - Mon Jan 05, 5:34AM CST
Merger activity decreased last week with two new mergers announced and three deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
NWBI: 11.91 (+0.08), TLM: 7.63 (-0.03), LO: 67.30 (-0.80), MTB: 123.90 (+0.52), MFI: 10.43 (+0.23), CNL: 53.80 (+0.10), SMPL: 17.70 (+0.20), WMGI: 25.68 (+0.17), ROC: 79.20 (+0.33), CFN: 59.81 (+0.01), HTH: 19.42 (+0.13), AUXL: 36.47 (-0.06), VSCI: 0.47 (unch), CBIN: 27.23 (+0.08), UPI: 1.27 (unch), CMSB: 13.19 (+0.13), CODE: 35.99 (+0.03), ESYS: 17.46 (+0.01), SIBC: 21.10 (+0.22), CHYR: 2.81 (+0.01), ATLS: 30.17 (+0.27), RNR: 103.80 (-0.64), COV: 106.71 (-1.36), HAL: 44.19 (+1.42), FDO: 77.86 (+0.31), EDS: 1.55 (+0.01), HCBK: 9.92 (+0.03), HBNK: 21.40 (+0.25), ESBF: 17.77 (+0.05), POM: 27.06 (-0.04), AMRE: 26.51 (unch), APAGF: 14.15 (-0.10), RNA: 18.65 (unch), XWES: 5.46 (-0.03), LNBB: 17.74 (-0.01), TRLA: 46.89 (+0.74), GRT: 14.06 (+0.10), PETM: 82.70 (+0.03), GFIG: 6.03 (-0.03), PTRY: 36.72 (+0.05), CIMT: 8.83 (+0.03), COBK: 13.41 (unch), ACT: 285.37 (+3.71), SWY: 35.10 (-0.04), ASYS: 9.87 (+0.30), NBCB: 35.20 (+0.28), MIG: 8.35 (unch), CVD: 107.08 (+0.05), VIAS: 17.37 (-0.02), BIRT: 6.60 (+0.01), AGN: 229.49 (+1.87), CACQ: 7.72 (+0.12), T: 34.66 (+0.05), IRF: 39.98 (-0.01), OILT: 44.69 (+0.29), APL: 27.30 (+0.85), CQB: 14.49 (unch), VOLC: 17.98 (+0.03), DTV: 87.51 (-0.32), SWS: 6.91 (-0.01), VYFC: 19.72 (+0.12), BNCN: 16.66 (-0.04), FRNK: 21.71 (+0.53), HVB: 26.29 (-0.36), TEG: 75.56 (-1.61), TWC: 149.74 (+2.21), DWSN: 6.89 (-0.42), GTIV: 19.19 (-0.23), SUSQ: 13.48 (+0.01), TRW: 103.60 (-0.06), BHI: 64.31 (+1.93), PTP: 76.57 (-0.13), HBOS: 24.84 (+0.14), NBTF: 29.50 (+0.20), FFKY: 3.90 (-0.20), DRC: 81.21 (+0.31), AVIV: 36.45 (-0.08), BKYF: 47.75 (-0.30), HE: 33.14 (-0.22), BTUI: 2.62 (-0.04), NGLS: 45.82 (+1.66), RNST: 27.87 (+0.28), HCT: 13.11 (+0.09), PL: 69.95 (-0.01), AVNR: 16.96 (unch), CBST: 101.94 (+0.14), RVBD: 20.85 (-0.03), SAPE: 24.98 (-0.02), PRLS: 6.96 (-0.02), PENX: 18.87 (-0.01), IGT: 17.20 (-0.04), CMCSA: 59.47 (+1.09)
BioMarin's Vimizim OK'd in Japan for Morquio A Syndrome - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 4:10PM CST
BioMarin's (BMRN) Vimizim gained Japanese approval for the treatment of patients suffering from mucopolysaccharidosis type IVA or Morquio A syndrome.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), ANIP: 62.69 (-0.43), ACOR: 36.14 (-0.51)
PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74), BIOD: 1.38 (-0.14)
BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's Proposed Acquisition of Prosensa
GlobeNewswire - Wed Dec 24, 12:15PM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Prosensa Holding N.V. (Nasdaq:RNA) today announced the expiration of the mandatory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act" , which occurred at 11:59 p.m. on December 23, 2014, with respect to BioMarin's pending acquisition of Prosensa.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
BioMarin CEO Sees Big Future For Prosensa Drug
at Investor's Business Daily - Tue Dec 23, 3:11PM CST
BioMarin Pharmaceuticals raised a few eyebrows last month when it announced its latest buyout. BioMarin (BMRN) agreed to pay $680 million upfront for Prosensa Holding (RNA), a Dutch biotech developing a drug for Duchenne muscular dystrophy called...
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), PTCT: 53.37 (-0.74), GSK: 47.94 (+1.99)
Prosensa Announces Voluntary Delisting and Advance Liquidation Distribution
GlobeNewswire - Tue Feb 10, 11:16AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"
, the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that, on February 11, 2015, it will file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act" (the "Form 25" , with the Securities Exchange Commission ("SEC" in order to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares" from the NASDAQ Global Select Market ("NASDAQ" , which will become effective 10 days after filing. NASDAQ has advised the Company that it will suspend trading of the Shares after the market closes on February 11, 2015. As such, shareholders of the Company will not be able to trade their shares on NASDAQ thereafter. BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
3 Biotech Stocks to Buy in February
Motley Fool Staff - Motley Fool - Mon Feb 02, 9:01AM CST
When it comes to figuring out the best stocks to buy in any given month or year, crystal balls can be hazy, but our top Motley Fool contributors have scoured SEC filings, read industry trade journals, and crunched numbers to uncover three biotech...
FLML: 14.15 (+0.15), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), CELG: 115.88 (+0.16)
Prosensa Announces Intent to Voluntarily Delist From NASDAQ
GlobeNewswire - Fri Jan 30, 7:36AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"
, the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that it intends to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares" , from the NASDAQ Global Select Market ("NASDAQ" . Upon satisfaction of the applicable requirements for deregistration, Prosensa also intends to deregister the Shares under the Securities Exchange Act of 1934, as amended (the "Exchange Act" and to suspend its reporting obligations under the Exchange Act once it is eligible to do so. BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
BioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period
GlobeNewswire - Fri Jan 30, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the final results of, and the completion of the subsequent offering period relating to, the previously announced tender offer by its subsidiaries, BioMarin Falcons B.V. and BioMarin Giants B.V. (together, "Purchaser"
, to acquire all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA) at a purchase price of $17.75 per share, net to the seller in cash (the "Cash Consideration" , plus one non-transferrable contingent value right to receive cash payments of up to $4.14 per share in the aggregate upon the achievement of certain product approval milestones ("CVR" , in each case, without interest thereon and less any applicable withholding taxes. BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 5:00PM CST
BioMarin (BMRN) will be raising approximately $792.6 million through the issuance of the shares in order to finance the Prosensa acquisition.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), ALXN: 182.29 (+6.02), AMGN: 153.48 (+0.30)
Marathon Pharma DMD drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:38PM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), PFE: 34.64 (-0.23), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
3 Warning Signs You've Invested in a Dangerous Biotech Stock
Motley Fool Staff - Motley Fool - Sat Jan 17, 10:59AM CST
Source: Flickr user epSos .de . There might not be a bell that will ring to alert investors when they have put their money in the wrong biotech stock, but there are warning signals that can help them avoid owning the most dangerous biotech...
INO: 6.80 (-0.15), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), GSK: 47.94 (+1.99)
BioMarin Announces Completion of Tender Offer for Prosensa's Shares and Commences Subsequent Offering Period
GlobeNewswire - Thu Jan 15, 7:59AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it completed the initial offering period for the previously announced tender offer for all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA). As a result, BioMarin will purchase approximately 93.4% of Prosensa's outstanding shares pursuant to the initial offering period for the tender offer. BioMarin also announced that it has commenced a subsequent offering period to provide Prosensa shareholders who have not yet tendered their shares the opportunity to do so. The subsequent offering period is scheduled to expire at 6:00 p.m., New York City time, on January 29, 2015.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
Update: BioMarin To Acquire Prosensa Holding N.V.
Maudes Capital - at Seeking Alpha - Thu Jan 15, 7:27AM CST
BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
BioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 4:10PM CST
BioMarin (BMRN) raised its 2014 guidance for Vimizim sales and presented encouraging interim data from an ongoing phase I/II pivotal study on Batten disease candidate, BMN 190.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23)
Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer
GlobeNewswire - Tue Jan 13, 7:56AM CST
Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that during an extraordinary general meeting of shareholders held today, Prosensa obtained shareholder approval for certain matters relating to the previously disclosed tender offer by BioMarin to purchase all of the outstanding shares of Prosensa.
RNA: 18.65 (unch)
Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year
at The Street - Mon Jan 12, 8:47AM CST
The company presents at the J.P. Morgan Healthcare Conference on Thursday.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), SRPT: 12.76 (+0.11)
Why Sarepta Therapeutics Inc. Stock Tumbled 15% in December
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 09, 6:04AM CST
SRPT data by YCharts What: Shares of Sarepta Therapeutics , a clinical-stage biotechnology company primarily focused on developing therapies to treat Duchenne muscular dystrophy, or DMD, tumbled 15% in December according to data from ...
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), SRPT: 12.76 (+0.11)
Cramer's Mad Money - Best Biotechs Of 2014 (1/6/15)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Jan 07, 4:38AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday January 6. Best Biotechs of 2014: Isis Pharmaceuticals (NASDAQ: ISIS ), BioMarin (NASDAQ: BMRN ), OvaScience (NASDAQ: OVAS ), Agios (NASDAQ: AGIO ),...
BLUE: 90.70 (+0.93), GE: 25.15 (+0.26), BMRN: 100.76 (+1.98), OVAS: 44.32 (+0.87), XOM: 93.37 (+1.00), TGTX: 13.13 (-0.19), WFC: 55.33 (+0.47), BA: 149.73 (+1.64), GLUU: 5.12 (+0.14), LUV: 43.30 (-0.20), T: 34.66 (+0.05), TTWO: 28.40 (+0.96), GT: 25.91 (-0.30), SAVE: 79.32 (-0.80), ISIS: 63.86 (-0.43), RNA: 18.65 (unch), IBM: 160.40 (+1.88), AAL: 48.39 (+0.51), MCD: 95.65 (+0.56), RCPT: 115.83 (-0.66), AGI: 5.78 (+0.03), TWTR: 48.50 (+0.55), CVX: 112.78 (+1.92), VZ: 49.31 (-0.21)
Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains
at The Street - Tue Jan 06, 7:25PM CST
The markets are presenting a buying opportunity at current levels, but only if you know which stocks to buy, Cramer says.
TSLA: 203.77 (+0.89), GE: 25.15 (+0.26), OVAS: 44.32 (+0.87), NMM: 12.37 (+0.24), XOM: 93.37 (+1.00), T: 34.66 (+0.05), ESPR: 67.13 (-0.33), IBM: 160.40 (+1.88), IRE: 14.54 (+0.81), DTV: 87.51 (-0.32), PTCT: 53.37 (-0.74), RCPT: 115.83 (-0.66), TEG: 75.56 (-1.61), PPG: 236.77 (+3.74), WAG: 76.05 (-0.49), BLUE: 90.70 (+0.93), TGTX: 13.13 (-0.19), WFC: 55.33 (+0.47), BA: 149.73 (+1.64), RAD: 8.34 (+0.25), ISIS: 63.86 (-0.43), RNA: 18.65 (unch), ACHN: 10.89 (-0.20), JCP: 8.05 (+0.14), CVS: 102.63 (-0.37), MCD: 95.65 (+0.56), AGIO: 118.55 (+0.11), CVX: 112.78 (+1.92), VZ: 49.31 (-0.21), FOLD: 8.36 (-0.11)
Merger Arbitrage Mondays - January 5, 2015
Asif Suria - at Seeking Alpha - Mon Jan 05, 5:34AM CST
Merger activity decreased last week with two new mergers announced and three deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
NWBI: 11.91 (+0.08), TLM: 7.63 (-0.03), LO: 67.30 (-0.80), MTB: 123.90 (+0.52), MFI: 10.43 (+0.23), CNL: 53.80 (+0.10), SMPL: 17.70 (+0.20), WMGI: 25.68 (+0.17), ROC: 79.20 (+0.33), CFN: 59.81 (+0.01), HTH: 19.42 (+0.13), AUXL: 36.47 (-0.06), VSCI: 0.47 (unch), CBIN: 27.23 (+0.08), UPI: 1.27 (unch), CMSB: 13.19 (+0.13), CODE: 35.99 (+0.03), ESYS: 17.46 (+0.01), SIBC: 21.10 (+0.22), CHYR: 2.81 (+0.01), ATLS: 30.17 (+0.27), RNR: 103.80 (-0.64), COV: 106.71 (-1.36), HAL: 44.19 (+1.42), FDO: 77.86 (+0.31), EDS: 1.55 (+0.01), HCBK: 9.92 (+0.03), HBNK: 21.40 (+0.25), ESBF: 17.77 (+0.05), POM: 27.06 (-0.04), AMRE: 26.51 (unch), APAGF: 14.15 (-0.10), RNA: 18.65 (unch), XWES: 5.46 (-0.03), LNBB: 17.74 (-0.01), TRLA: 46.89 (+0.74), GRT: 14.06 (+0.10), PETM: 82.70 (+0.03), GFIG: 6.03 (-0.03), PTRY: 36.72 (+0.05), CIMT: 8.83 (+0.03), COBK: 13.41 (unch), ACT: 285.37 (+3.71), SWY: 35.10 (-0.04), ASYS: 9.87 (+0.30), NBCB: 35.20 (+0.28), MIG: 8.35 (unch), CVD: 107.08 (+0.05), VIAS: 17.37 (-0.02), BIRT: 6.60 (+0.01), AGN: 229.49 (+1.87), CACQ: 7.72 (+0.12), T: 34.66 (+0.05), IRF: 39.98 (-0.01), OILT: 44.69 (+0.29), APL: 27.30 (+0.85), CQB: 14.49 (unch), VOLC: 17.98 (+0.03), DTV: 87.51 (-0.32), SWS: 6.91 (-0.01), VYFC: 19.72 (+0.12), BNCN: 16.66 (-0.04), FRNK: 21.71 (+0.53), HVB: 26.29 (-0.36), TEG: 75.56 (-1.61), TWC: 149.74 (+2.21), DWSN: 6.89 (-0.42), GTIV: 19.19 (-0.23), SUSQ: 13.48 (+0.01), TRW: 103.60 (-0.06), BHI: 64.31 (+1.93), PTP: 76.57 (-0.13), HBOS: 24.84 (+0.14), NBTF: 29.50 (+0.20), FFKY: 3.90 (-0.20), DRC: 81.21 (+0.31), AVIV: 36.45 (-0.08), BKYF: 47.75 (-0.30), HE: 33.14 (-0.22), BTUI: 2.62 (-0.04), NGLS: 45.82 (+1.66), RNST: 27.87 (+0.28), HCT: 13.11 (+0.09), PL: 69.95 (-0.01), AVNR: 16.96 (unch), CBST: 101.94 (+0.14), RVBD: 20.85 (-0.03), SAPE: 24.98 (-0.02), PRLS: 6.96 (-0.02), PENX: 18.87 (-0.01), IGT: 17.20 (-0.04), CMCSA: 59.47 (+1.09)
BioMarin's Vimizim OK'd in Japan for Morquio A Syndrome - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 4:10PM CST
BioMarin's (BMRN) Vimizim gained Japanese approval for the treatment of patients suffering from mucopolysaccharidosis type IVA or Morquio A syndrome.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), ANIP: 62.69 (-0.43), ACOR: 36.14 (-0.51)
PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74), BIOD: 1.38 (-0.14)
BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's Proposed Acquisition of Prosensa
GlobeNewswire - Wed Dec 24, 12:15PM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Prosensa Holding N.V. (Nasdaq:RNA) today announced the expiration of the mandatory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"
, which occurred at 11:59 p.m. on December 23, 2014, with respect to BioMarin's pending acquisition of Prosensa. BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
BioMarin CEO Sees Big Future For Prosensa Drug
at Investor's Business Daily - Tue Dec 23, 3:11PM CST
BioMarin Pharmaceuticals raised a few eyebrows last month when it announced its latest buyout. BioMarin (BMRN) agreed to pay $680 million upfront for Prosensa Holding (RNA), a Dutch biotech developing a drug for Duchenne muscular dystrophy called...
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), PTCT: 53.37 (-0.74), GSK: 47.94 (+1.99)
